While the FDA mulls whether to approve Protagonist Therapeutics’ hematology asset, the biotech is thinking it will pocket $400 million rather than split U.S. profits with its partner Takeda. | While ...

A Chinese phase 3 trial of Bristol Myers Squibb’s antibody-drug conjugate (ADC) has hit its dual primary survival endpoints, ...

Asahi Kasei has unveiled plans to acquire Aicuris in a deal worth 780 million euros ($920 million), marking the latest in a ...

Quantum Surgical is looking to become the “leader in the interventional radiology industry” with its buyout of Johnson & Johnson’s cancer ablation company NeuWave Medical. | Quantum Surgical is ...

Boehringer Ingelheim has penned a $500 million deal with a British biotech for a preclinical program the German pharma hopes could offer a fresh oral treatment approach to a variety of autoimmune a | ...

Accent Therapeutics has halted work on a solid tumor drug due to adverse events in a phase 1/2 study. | Accent Therapeutics has halted work on a solid tumor drug due to adverse events in a phase 1/2 ...

After promising to sell off 7% of its business back in November, Charles River Laboratories has delivered. | After promising to sell off 7% of its business back in November, Charles River Laboratories ...

In an effort to battle against what members feel is an existential threat to their business, a group of 10 domestic biotech companies have launched the Midsized Biotech Alliance of America with a ...

Following the launch of its Wegovy (semaglutide) pill at the beginning of the year, Novo Nordisk is committing as much as ...

After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate.

Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients ...

GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from ...